1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Profound Medical Corp.

Profound Medical Corp.

PRN.TO
Profound Medical Corp.CA flagToronto Stock Exchange
10.46
CAD
+0.71
- -
316.51MMarket Cap
Profound Medical Corp.
PRN.TO
(Toronto Stock Exchange)

Recent

price

10.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
0.64
0.19
0.38
0.42
0.34
0.32
0.34
0.43
0.53
0.59
Revenue per Share
-37.86
-4.98
-2.93
-2.44
-1.52
-1.37
-1.25
-1.5
-1.38
-1.34
-1.12
-1.41
-1.22
Basic EPS, GAAP
-13.57
-2.14
-2.79
-1.98
-1.34
-1.37
-1.21
-1.12
-1.24
-1.07
-0.95
-1.27
-1.21
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5.03
3.64
2.12
1.05
0.72
-0.73
4.71
2.88
0.79
0.23
1.47
1.19
0.92
Book Value per Share
6.15
4.24
2.61
0.72
1.4
0.84
5.36
3.74
2.47
1.45
2.43
2.19
1.86
Tangible Book Value per Share
- -
2
4
6
10
11
17
20
21
21
25
30
32
Basic Weighted Avg Shares
- -
- -
- -
4
2
4
7
7
7
7
11
16
19
Sales/Revenue/Turnover
- -
- -
- -
-359.49
-776.04
-357.07
-258.26
-440.72
-443.08
-397.99
-309.57
-256.27
-202.56
Operating Margin (%)
- -
- -
- -
1
1
2
2
2
2
1
1
1
- -
Depreciation Expense
-8
-12
-12
-15
-15
-15
-22
-31
-29
-28
-28
-43
-39
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-383.77
-797.88
-364.69
-296.03
-446.66
-429.11
-393.43
-260.45
-264.44
-206.76
Profit Margin (%)
1
14
13
6
22
15
93
73
58
36
62
70
59
Working Capital
2
4
3
- -
8
7
1
1
7
6
3
4
3
LT Debt
1
10
11
11
20
14
97
81
52
31
60
66
59
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-243.05
-139.49
-196.5
-222.46
- -
- -
-43.72
-76.1
-265.77
-134.92
-117.47
-141.15
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
5
- -
5
LT Borrowings
- -
4
- -
LT Finance Leases
- -
- -
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
36
36
Market Capitalization
142
237
203

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
42
76
70
Cash, Cash Equivalents & STI
25
60
50
Accounts Receivable, Net
8
7
9
Inventories
8
8
9
Total Current Liabilities
10
6
11
Payables & Accruals
1
3
3
ST Debt
5
- -
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
64.72%
2.16%
9.95%
Free Cash Flow
27.25%
15.48%
63.94%
Net Income, GAAP
15.53%
17.08%
53.04%
Sales/Revenue/Turnover
- -
19.63%
50.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
2
3
4
11
2025
3
2
5
6
16
2026
5
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.27
-0.28
-0.38
-0.21
-1.12
2025
-0.36
-0.52
-0.26
-0.27
-1.41
2026
-0.19
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Beyond Air, Inc. (XAIR)
ClearPoint Neuro, Inc. (CLPT)
Bio-View Ltd (BIOV.TA)
Nova Eye Medical Limited (ELXMF)
Shanghai MicroPort MedBot (Group) Co., Ltd. (2252.HK)
EDAP TMS S.A. American Depositary Shares (FOCL)
Business
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) develops and commercializes customizable, incision-free therapies that combine real-time magnetic resonance imaging, thermal ultrasound, robotically-driven ablation and closed-loop temperature feedback control for the radiation-free treatment of diseased tissue, primarily targeting prostate conditions and uterine fibroids; its lead product, TULSA-PRO, provides transurethral ultrasound ablation for localized prostate cancer, radio-recurrent prostate cancer, benign prostatic hyperplasia and palliation in advanced cases, offering customizable whole-gland or partial ablation while preserving functional abilities such as urinary continence and sexual function, with CE mark, Health Canada approval and U.S. FDA 510(k) clearance; it also markets Sonalleve, a MR-HIFU platform for non-invasive treatment of uterine fibroids and bone metastases pain palliation, approved by the China FDA for fibroids and under exploration for abdominal cancers and hyperthermia applications. Founded in 2008 and headquartered in Mississauga, Ontario, Canada, the company operates globally with key commercial activities in North America, Europe and Asia Pacific, serving urologists, oncologists and interventional radiologists through direct sales, partnerships and distribution networks. Recent developments include an exclusive distribution and supply agreement with Getz Healthcare in November 2025 to commercialize TULSA-PRO in Australia and New Zealand, regaining exclusive Canadian distribution rights from Knight Therapeutic via a one-time payment in November 2025, and a strategic partnership between Texas Prostate and Dallas Medical Center to launch a TULSA program expanding Medicare access in the U.S.

Company News

APIChatGPT

  • globenewswire.com

    Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation

  • globenewswire.com

    Profound Medical to Participate in the Stifel 2025 Healthcare Conference